Protein kinase A negatively regulates VEGF-induced AMPK activation by phosphorylating CaMKK2 at serine 495.


Journal

The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R

Informations de publication

Date de publication:
18 09 2020
Historique:
received: 15 07 2020
revised: 19 08 2020
accepted: 01 09 2020
pubmed: 2 9 2020
medline: 23 2 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Activation of AMP-activated protein kinase (AMPK) in endothelial cells by vascular endothelial growth factor (VEGF) via the Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) represents a pro-angiogenic pathway, whose regulation and function is incompletely understood. This study investigates whether the VEGF/AMPK pathway is regulated by cAMP-mediated signalling. We show that cAMP elevation in endothelial cells by forskolin, an activator of the adenylate cyclase, and/or 3-isobutyl-1-methylxanthine (IBMX), an inhibitor of phosphodiesterases, triggers protein kinase A (PKA)-mediated phosphorylation of CaMKK2 (serine residues S495, S511) and AMPK (S487). Phosphorylation of CaMKK2 by PKA led to an inhibition of its activity as measured in CaMKK2 immunoprecipitates of forskolin/IBMX-treated cells. This inhibition was linked to phosphorylation of S495, since it was not seen in cells expressing a non-phosphorylatable CaMKK2 S495C mutant. Phosphorylation of S511 alone in these cells was not able to inhibit CaMKK2 activity. Moreover, phosphorylation of AMPK at S487 was not sufficient to inhibit VEGF-induced AMPK activation in cells, in which PKA-mediated CaMKK2 inhibition was prevented by expression of the CaMKK2 S495C mutant. cAMP elevation in endothelial cells reduced basal and VEGF-induced acetyl-CoA carboxylase (ACC) phosphorylation at S79 even if AMPK was not inhibited. Together, this study reveals a novel regulatory mechanism of VEGF-induced AMPK activation by cAMP/PKA, which may explain, in part, inhibitory effects of PKA on angiogenic sprouting and play a role in balancing pro- and anti-angiogenic mechanisms in order to ensure functional angiogenesis.

Identifiants

pubmed: 32869834
pii: 226282
doi: 10.1042/BCJ20200555
doi:

Substances chimiques

VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Colforsin 1F7A44V6OU
Serine 452VLY9402
Cyclic AMP-Dependent Protein Kinases EC 2.7.11.11
CAMKK2 protein, human EC 2.7.11.17
Calcium-Calmodulin-Dependent Protein Kinase Kinase EC 2.7.11.17
AMP-Activated Protein Kinases EC 2.7.11.31
1-Methyl-3-isobutylxanthine TBT296U68M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3453-3469

Subventions

Organisme : Medical Research Council
ID : MC_U120027537
Pays : United Kingdom

Informations de copyright

© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Katrin Spengler (K)

Institute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, 07743 Jena, Germany.

Darya Zibrova (D)

Institute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, 07743 Jena, Germany.

Angela Woods (A)

MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London W12 0NN, U.K.

Christopher G Langendorf (CG)

St Vincent's Institute and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia.

John W Scott (JW)

St Vincent's Institute and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia.
Mary MacKillop Institute for Health Research, Australian Catholic University, 215 Spring Street, Melbourne 3000, Australia.
The Florey Institute of Neuroscience and Mental Health, Parkville 3052, Australia.

David Carling (D)

MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London W12 0NN, U.K.

Regine Heller (R)

Institute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, 07743 Jena, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH